![]() Zaleplon and daridorexant both increase sedation. Use Caution/Monitor.Ĭomment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression). Use Caution/Monitor.Ĭimetidine will increase the level or effect of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Įither increases effects of the other by sedation. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.Ĭarbamazepine will decrease the level or effect of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Zaleplon increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Avoid or Use Alternate Drug.Įither increases toxicity of the other by sedation. Valerian and zaleplon both increase sedation. Monitor closely for signs of respiratory depression and sedation. Limit dosages and durations to the minimum required. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Avoid taking selinexor with other medications that may cause dizziness or confusion.Įither increases toxicity of the other by pharmacodynamic synergism. Patients treated with selinexor may experience neurological toxicities. Additive CNS depression may lead to hypotension, profound sedation, respiratory depression, or coma Zaleplon and oxycodone both increase sedation. Avoid or Use Alternate Drug.Ĭomment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient. Use of lemborexant with other drugs to treat insomnia is not recommended.Įither increases effects of the other by Other (see comment). Monitor for hypotension, respiratory depression, and profound sedation.Įither increases effects of the other by sedation. Consider dose reduction of either or both agents to avoid serious adverse effects. ![]() ![]() Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Monitor closely for signs of respiratory depression and sedation.Įither increases effects of the other by pharmacodynamic synergism. Profound sedation, respiratory depression, coma, and death may result if coadministered. Coadministration with alcohol or sedative hypnotics are contraindicated because of additive CNS depression.Įither increases toxicity of the other by pharmacodynamic synergism. Zaleplon, calcium/magnesium/potassium/sodium oxybates.Įither increases effects of the other by pharmacodynamic synergism.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |